An employee checks the production of chloroquine phosphate at a pharmaceutical company in Nantong city in east China's Jiangsu province, Thursday, Feb. 27, 2020. (Getty Images)
March 24, 2020 07:06 AM EDTUpdated 01:02 PM
Coronavirus

'I have a feel­ing': Trump-en­dorsed malar­ia drug fails to pass muster in small Chi­nese coro­n­avirus study

Natalie Grover

Reporter

De­spite the FDA’s re­luc­tance to en­dorse with­out de­fin­i­tive clin­i­cal tri­al da­ta the decades-old an­ti-malar­i­al drugs chloro­quine and de­riv­a­tive hy­drox­y­chloro­quine as treat­ments to com­bat the coro­n­avirus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times